SCHEMBL24257762

SCHEMBL24257762

COc1c(C(=O)O)ncc(Cc2ccccc2)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
KMT2A Q03164 2/20 0.40
LNPEP Q9UIQ6 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
RNASEH1 O60930 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257733 0.82 EGLN1 (0.49) KMT2AMEN1
SCHEMBL27833087 0.78 PTPN1 (0.44) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL28346190 0.77 CNR2 (0.48) CNR2GPR55KMT2AMEN1ALDH1A1
SCHEMBL24257761 0.74 CNR2 (0.40) CNR2GPR55ALDH1A1LMNAGAA
SCHEMBL30546848 0.74 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL24257821 0.74 TTR (0.44) KMT2AMEN1POLBSMN1; SMN2
SCHEMBL24257708 0.74 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL5583586 0.73 PDE4D (0.51) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL6382788 0.72 MRGPRX4 (0.45) KMT2ALNPEPMEN1SMN1; SMN2VNN1
SCHEMBL26260122 0.72 PTPN1 (0.53) KMT2AMEN1ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 CNR2 4211/4885GPR55 3258/4885KMT2A 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.